126
Participants
Start Date
January 11, 2012
Primary Completion Date
April 9, 2014
Study Completion Date
December 15, 2014
INNO-206
INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
Doxorubicin
Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
Royal North Shore, St Leonards
The Crown Princess Mary Cancer Centre Westmead, Sydney
Border Medical Oncology, Wodonga
Royal Perth Hospital, Perth
Pennsylvania Hematology Oncology Associates, Philadelphia
Vinnytsya Regional Clinical Oncologic Dispensary, Surgical Department, Vinnytsia
"Municipal Institution Dnipropetrovsk City Multi-Field Clinical Hospital #4 of Dnipropetrovsk Regional Councel", Dnipropetrovsk
University of Iowa, Iowa City
"Municipal institution Chernivtsi Regional Clinical Oncologic Dispensary,", Chernivtsi
"State Institution Institute of Medical Radiology named after S.P.Grygoryev of National Academy of Medical Sciences of Ukraine,", Kharkiv
Lviv State Oncological Regional Treatment - Diagnostics Center, Chemotherapy Department, Lviv
Sarcoma Oncology Center, Santa Monica
Stanford University, Stanford
Delhi State Cancer Institute, Mandoli
Blokhin Cancer Research Center, Moscow
Hemato Oncology Clinic, Vedanta Institute of Medical Science, Ahmedabad
Hemato Oncology Clinic, Vedanta Institute of Medical Science, Thaltej
Tata Memorial Hospital, Department of Medical Oncology, Mumbai
"Oncological Institute Prof. Dr. I. Chiricuta, Cluj-Napoca", Cluj-Napoca
Delhi State Cancer Institute, Pune
Jehangir Clinical Development Centre Pvt Ltd, Pune
Noble Hospital Clinical Research Department 1st Floor, Hadapsar
"State Healthcare Institution Republican Clinical Oncological Center of the Ministry of Health of Republic of Tatarstan", Kazan'
Curie Manavata Cancer Centre, Nashik
"Spitalul Judetean de Urgenta Dr. Constantin Opris Baia-Mare, Sectia Oncologie", Baia Mare
Christian Medical College, Vellore
Clinical County Hospital Mures, Medical Oncology Department, Târgu Mureş
M.S. Ramaiah Medical College and Hospitals, Bangalore
CTRC Institute for Drug Development, University of Texas, San Antonio
Epworth HealthCare Clinical Trials and Research Centre, Richmond
Royal Hobart Hospital, Hobart
Mount Medical Centre, Perth
State Health Centre Oncology Department, Budapest
Medisprof SRL, Cluj-Napoca
Lead Sponsor
ImmunityBio, Inc.
INDUSTRY